The notices it replaced
Its page was not saved, so the notices it replaced are not known.
Who won it before
16 competing awards (new and renewals) from FY2014 to FY2025 under this notice and the notices it replaced: $7,160,805 in first-year total cost, median $440,870.
Most frequent study sections
- Special Emphasis Panel[ZCA1 SRLB-C (J1)]16
Most frequent institutions
- DANA-FARBER CANCER INST2
- MAYO CLINIC ROCHESTER2
- UNIV OF NORTH CAROLINA CHAPEL HILL2
- BAYLOR COLLEGE OF MEDICINE1
- JOHNS HOPKINS UNIVERSITY1
| FY | Project | PIs | Institution | First-year cost | Study section |
|---|---|---|---|---|---|
| 2014 | (PQD3) Mechanisms of prolonged initial disease-free survival in glioblastoma1R01CA184320-01 | SARKARIA, JANN N. | MAYO CLINIC ROCHESTER, MN | $669,147 | ZCA1 |
| 2014 | (PQD5) Avatar-directed Treatment for Ovarian Cancer1R01CA184502-01 | HALUSKA, PAUL | MAYO CLINIC ROCHESTER, MN | $621,606 | ZCA1 |
| 2014 | (PQD1) Evolution of vemurafenib resistance in circulating melanoma cells1R01CA185151-01 | NOVINA, CARL D | DANA-FARBER CANCER INST, MA | $603,086 | ZCA1 |
| 2014 | (PQD1) lmpact of cytotoxic and targeted therapy on clonal evolution of CLL1R01CA184922-01 | WU, CATHERINE JU-YING | DANA-FARBER CANCER INST, MA | $553,684 | ZCA1 |
| 2014 | (PQD2)New Biomarkers and Pathways to Enhance Cure in Ovarian Cancers1R01CA184968-01 | FANTL, WENDY JANESIKIC, BRANIMIR I | STANFORD UNIVERSITY, CA | $509,161 | ZCA1 |
| 2014 | (PQD5) imaging systemic tissue injuries induced by anticancer drugs1R01CA185214-01 | MAZAR, ANDREW PZHAO, MING | NORTHWESTERN UNIVERSITY AT CHICAGO, IL | $488,338 | ZCA1 |
| 2014 | (PQD5) Mass Profiling Melanoma Responses to Improve Therapy Choices and Prognosis1R01CA185189-01 | REED, JASON CTEITELL, MICHAEL A | UNIVERSITY OF CALIFORNIA LOS ANGELES, CA | $481,506 | ZCA1 |
| 2014 | (PQD3)Molecular Profiles associated with Long-Term Survival in pancreas Cancer1R01CA185357-01 | AHUJA, NITAEASWARAN, HARIHARANIACOBUZIO-DONAHUE, CHRISTINE A | JOHNS HOPKINS UNIVERSITY, MD | $459,341 | ZCA1 |
| 2014 | (PQD6) Hypothalamic Inflammation in the Initiation of Cachexia1R01CA184324-01 | MARKS, DANIEL L. | OREGON HEALTH & SCIENCE UNIVERSITY, OR | $422,399 | ZCA1 |
| 2014 | (PQD5) Predicting Anti-Cancer Efficacy through Tumor Profiling1R01CA185353-01 | PEROU, CHARLES MSHARPLESS, NORMAN E | UNIV OF NORTH CAROLINA CHAPEL HILL, NC | $405,890 | ZCA1 |
| 2014 | (PQD1) Clonal heterogeneity and targeted therapy resistance in melanoma1R01CA185072-01 | SEKULIC, ALEKSANDAR NONE | MAYO CLINIC ARIZONA, AZ | $382,030 | ZCA1 |
| 2014 | (PQD5) A novel genetic strategy to predict efficacy of anti-CD20 antibodies1R01CA185372-01 | RICHARDS, KRISTY L | UNIV OF NORTH CAROLINA CHAPEL HILL, NC | $329,519 | ZCA1 |
| 2014 | (PQD1) An Iterative Approach for Overcoming Evolving Targeted Therapy Resistance1R01CA185404-01 | WU, LANI F | UNIVERSITY OF CALIFORNIA, SAN FRANCISCO, CA | $327,937 | ZCA1 |
| 2014 | (PQD6)The Role of Immune Homeostasis in Protection from Cancer Cachexia1R01CA185349-01 | DAVIES, JOANNA D | SAN DIEGO BIOMEDICAL RESEARCH INSTITUTE, CA | $325,000 | ZCA1 |
| 2014 | (PQD-5) Patient derived orthotopic xenograft models for drug response prediction1R01CA185402-01 | LI, XIAONAN | BAYLOR COLLEGE OF MEDICINE, TX | $324,033 | ZCA1 |
| 2014 | (PQD-1) Selective pressure of antiandrogens on castration resistant prostate canc1R01CA185509-01 | GHOSH, PARAMITA M. | UNIVERSITY OF CALIFORNIA AT DAVIS, CA | $258,128 | ZCA1 |
Data: Grants.gov's daily extract and NIH's notice pages and award files, in ScienceGraph release conductgrants-2026-11-10-0.1.1. An award is listed only where NIH's own record names the notice, and a PI only by NIH's profile ID. Grants.gov and NIH do not endorse ScienceDex.